Komori
Other Disclosures4591RIBOMIC Inc.Pharmaceuticals

The transcript of our financial results briefing for the fiscal year ending March 2026 has been published on Logmi Finance.

A transcript of the earnings presentation for the fiscal year ending March 2026 was posted on Logmi Finance. No new business or contract was announced; the content of the existing earnings presentation has simply been made available for viewing.

Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

Logmi Finance (earnings presentation transcript articles)
Applicable field (uses covered by this announcement)

Disclosure of investor relations information

Launch date29 May 2026 (already posted)
Relationship between the counterparty and the company
RIBOMIC Inc.4591
Relationship with the Company

Logmi Finance posts transcripts of our earnings presentations.

CounterpartyLogmi Inc.

The company that operates Logmi Finance. Other company information: not disclosed

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Logmi Finance (https://finance.logmi.jp/articles/384952)

Announced details
ItemDetails
Names of Products / Services CoveredLogmi Finance (earnings presentation transcript articles)
CounterpartyLogmi Inc.
Counterparty overviewThe company that operates Logmi Finance. Other company information: not disclosed
Relationship with the CompanyLogmi Finance posts transcripts of our earnings presentations.
Launch date29 May 2026 (already posted)
Applicable areaDisclosure of investor relations information
SourceLogmi Finance (https://finance.logmi.jp/articles/384952)
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The stated purpose is to disclose information broadly to investors, facilitate contact with investors, and support an appropriate valuation of the company.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
The transcript of our financial results briefing for the fiscal year ending March 2026 has been published on Logmi Finance. | RIBOMIC Inc. (4591) timely disclosure | Komori